

Resource Summary Report

Generated by [dkNET](#) on Sep 6, 2026

LN-428

RRID:CVCL_3959

Type: Cell Line

Proper Citation

RRID:CVCL_3959

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3959

Proper Citation: RRID:CVCL_3959

Description: Cell line LN-428 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Glioblastoma

Defining Citation: [PMID:7693337](#), [PMID:7732013](#), [PMID:8509230](#), [PMID:9842975](#), [PMID:10416987](#), [PMID:14614447](#), [PMID:14655754](#), [PMID:17595512](#), [PMID:22570425](#), [PMID:25984343](#), [PMID:31068700](#)

Comments: Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LN-428

Synonyms: LN 428, LN428

Cross References: BTO:BTO_0002216, EFO:EFO_0022712, BioSample:SAMN10988393, cancercellines:CVCL_3959, Cell_Model_Passport:SIDM01642, Cosmic:849870, Cosmic:2516030, DepMap:ACH-000455, GEO:GSM1638653, GEO:GSM1638654, GEO:GSM1638655, IARC_TP53:2573, Pharmacodb:LN428_846_2019, Wikidata:Q54902783

ID: CVCL_3959

Record Creation Time: 20220427T220731+0000

Record Last Update: 20260905T181035+0000

Ratings and Alerts

No rating or validation information has been found for LN-428.

No alerts have been found for LN-428.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

de Gooijer MC, et al. (2026) Disconnect between in vitro and in vivo efficacy of the MPS1 inhibitor NTRC 0066-0 against glioblastoma. Cellular oncology (Dordrecht, Netherlands), 49(2), 46.

Zhang Z, et al. (2026) Multi-omics profiling-derived signature links cellular ecosystem to glioblastoma prognosis. iScience, 29(6), 115982.

Sallbach J, et al. (2024) The cell cycle inhibitor p21CIP1 is essential for irinotecan-induced senescence and plays a decisive role in re-sensitization of temozolomide-resistant glioblastoma cells to irinotecan. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 181, 117634.

Nguyen TT, et al. (2023) Epigenetic silencing of HTATIP2 in glioblastoma contributes to treatment resistance by enhancing nuclear translocation of the DNA repair protein MPG. Molecular oncology, 17(9), 1744.

Berberich A, et al. (2020) LAPTM5-CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance. Frontiers in oncology, 10, 747.